CFP
HOME HELP CONTACT US FEEDBACK SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES SEARCH
QUICK SEARCH:   [advanced]


     

Can Fam Physician
Vol. 53, No. 1, January 2007, pp.50 - 54
Copyright © 2007 by The College of Family Physicians of Canada
This Article
Right arrow Résumé
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in CFP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Massoud, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Massoud, F.

Révision clinique

Maladie d’Alzheimer

Fadi Massoud, MD, FRCPC
Professeur adjoint de clinique au Département de médecine de l’Université de Montréal et interniste-gériatre au Service de gériatrie de l’Hôpital Notre-Dame à Montréal

Correspondance à: Dr Fadi Massoud, Hôpital Notre-Dame, Service de gériatrie, 1560, Sherbrooke Est, Montréal, (Québec) H2L 2M1; téléphone: 514 890-8000, poste 26769; télécopieur: 514 412-7506; courriel: fadi-massoud{at}videotron.ca

OBJECTIVE Alzheimer disease (AD) is the most common form of dementia. There have been many advances in the pharmacological treatment of AD in recent years. This article discusses 2 of these advances: vascular prevention and a new molecule, memantine.

QUALITY OF EVIDENCE The conclusions and recommendations in this article are based on data from studies providing level I and level II evidence.

MAIN MESSAGE Recent data suggest that vascular disease plays an important role in the physiopathology of AD. Memantine is a non-competitive, low-affinity N-methyl-D-aspartate receptor antagonist of glutamate that offers a very attractive efficacy and safety profile for treating moderate to severe AD.

CONCLUSION The prevention and treatment of vascular risk factors should be an integral part of the management of AD. For the treatment of moderate to severe AD, memantine is a new option that is effective and well tolerated.


Related articles in CFP:

Exploring uncertainty
Diane Kelsall
CFP 2007 53: 11. [Full Text]  

Explorer l’incertitude
Diane Kelsall
CFP 2007 53: 11. [Full Text]  



This article has been cited by other articles:


Home page
 cfpHome page
J. Lexchin
Different conclusions about memantine
Can Fam Physician, March 1, 2007; 53(3): 403 - 404.
[Full Text] [PDF]

Home page
 cfpHome page
F. Massoud
Response
Can Fam Physician, March 1, 2007; 53(3): 404 - 404.
[Full Text] [PDF]


HOME HELP CONTACT US FEEDBACK SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES SEARCH
Copyright © 2007 by The College of Family Physicians of Canada.